Veru (NASDAQ:VERU) versus Elanco Animal Health (NYSE:ELAN) Financial Survey

Veru (NASDAQ:VERU – Get Free Report) and Elanco Animal Health (NYSE:ELAN – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Profitability

This table compares Veru and Elanco Animal Health’s net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Veru and Elanco Animal Health, as reported by MarketBeat.

Veru presently has a consensus target price of $24.50, indicating a potential upside of 876.10%. Elanco Animal Health has a consensus target price of $29.70, indicating a potential upside of 33.71%. Given Veru’s higher possible upside, equities analysts plainly believe Veru is more favorable than Elanco Animal Health.

Risk and Volatility

Veru has a beta of -1.21, meaning that its stock price is 221% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Institutional and Insider Ownership

47.2% of Veru shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Veru and Elanco Animal Health”s revenue, earnings per share (EPS) and valuation.

Veru has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Summary

Elanco Animal Health beats Veru on 9 of the 15 factors compared between the two stocks.

About Veru

(Get Free Report)

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.